Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Uriel Pharmacy, Inc
WARNING LETTER
•Uriel Pharmacy, Inc•March 4, 2025

Uriel Pharmacy, Inc – FDA Warning Letter, Mar 4, 2025

Record Details

The FDA issued a Warning Letter to Uriel Pharmacy, Inc. following an inspection from February 25 to March 4, 2025, identifying significant Current Good Manufacturing Practice (CGMP) violations. The agency determined that the company"s drug products are adulterated due to these deficiencies. Furthermore, several of Uriel Pharmacy"s homeopathic ampule drug products, such as Aquilinum Taraxacum and Aurum 6X, are considered unapproved new drugs. A significant public health concern arises because these products, packaged in glass ampules, could be mistaken for injectable drugs, potentially leading to serious harm if misused.

Specific CGMP violations included a failure to establish and follow adequate control procedures for manufacturing processes and to validate their performance. The company also failed to conduct appropriate laboratory testing to verify the identity and strength of active ingredients, such as in Calendula 10%, Arnica 20%, and Viscum Mali 50, prior to product release. Inadequate aseptic manufacturing practices were observed, including improper cleaning methods and the use of non-sterile agents in cleanrooms, despite some products being processed for sterility. The regulatory framework cited includes 21 CFR parts 210 and 211, and sections 501(a)(2)(B), 505(a), and 301(d) of the FD&C Act.

Uriel Pharmacy is required to provide a comprehensive assessment of its in-process monitoring and sampling operations, a remediation plan to improve variation detection and controls, and a list of chemical specifications. If the company intends to produce sterile injectable drugs, it must fully comply with all CGMP requirements for sterile products, including validation of sterilization processes.

Company
Uriel Pharmacy, Inc
Inspection date
March 4, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Jill P. Furman (Director)
View Company Profile

ID · b6cf99df-afda-4732-898e-b89763a95471

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 211FD&C Act 501(a)(2)(B)FD&C Act 505(a)FD&C Act 301(d)21.U.S.C. 355(a)21 U.S.C. 331(d)21 CFR 211.110(a)21 CFR 211.165(a)

Full citation text and observation details available on the Dashboard.

Other documents for Uriel Pharmacy, Inc
  • 483 - 2025-03-04March 4, 2025

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Uriel Pharmacy, Inc
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.